Here are five pharmaceutical companies that filed for bankruptcy protection since Feb. 1:
1. Aceto Corp., based in New York, develops and sells human health products, pharmaceutical ingredients and performance chemicals. It filed for Chapter 11 bankruptcy Feb. 19. The decision was voluntary, made to facilitate the sale of its assets.
2. Immune Pharmaceuticals, a New Jersey-based biopharmaceutical company specializing in the development of treatments for immunologic and inflammatory diseases, filed for Chapter 11 bankruptcy Feb. 19. The drugmaker was unable to get funding to keep the company afloat, prompting its decision to file for bankruptcy protection.
3. Pernix Therapeutics, based in New Jersey, filed for Chapter 11 bankruptcy Feb. 18 amid lagging drug sales. The drugmaker also blamed its bankruptcy filing on increasing generic competition.
4. Imerys Talc America, which supplies talc for Johnson & Johnson's baby powder, filed for Chapter 11 bankruptcy Feb. 13. In its bankruptcy filing, the Vermont company cited the more than 14,000 claims the company faces in U.S. courts that allege Imerys' talc causes ovarian cancer or mesothelioma.
5. Novum Pharma, based in Chicago, filed for Chapter 11 bankruptcy Feb. 1. The drugmaker said that public backlash over its decision to raise the price of several dermatology products further increased prescription rejection rates and led to the bankruptcy filing.